Citius Pharmaceuticals Inc. (NASDAQ:CTXR) price closed higher on Monday, September 13, jumping 0.48% above its previous close.
A look at the daily price movement shows that the last close reads $2.08, with intraday deals fluctuated between $2.03 and $2.15. The company’s 5Y monthly beta was ticking 1.53. Taking into account the 52-week price action we note that the stock hit a 52-week high of $4.56 and 52-week low of $0.87. The stock added 12.97% on its value in the past month.
Citius Pharmaceuticals Inc., which has a market valuation of $308.07 million, is expected to release its quarterly earnings report Aug 12, 2021. Analysts tracking CTXR have forecast the quarterly EPS to shrink by -0.07 per share this quarter, while the same analysts predict the annual EPS to hit -$0.34 for the year 2021 and up to $0 for 2022.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give CTXR a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as Hold.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned CTXR a recommendation rating as follows: 0 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Citius Pharmaceuticals Inc. (CTXR) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that CTXR’s price is at present 4.11% off the SMA20 and 4.95% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 52.60, with weekly volatility standing at 6.57%. The indicator jumps to 6.31% when calculated based on the past 30 days. Citius Pharmaceuticals Inc. (NASDAQ:CTXR)’s beta value is holding at 1.54, while the average true range (ATR) indicator is currently reading 0.12. Considering analysts have assigned the stock a price target range of $10.00-$10.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $10.00. Based on this estimate, we see that current price is roughly -378.47% off the estimated low and -378.47% off the forecast high. Investors will no doubt be excited to see the share price fall to $10.00, which is the median consensus price, and at that level CTXR would be -378.47% from current price.
Turning out attention to how the Citius Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: CTXR’s stock is 0.48% on the day and 106.93% in the past 12 months. Another comparison is with Omeros Corporation (OMER) whose stock price was up 1.86% in the last trading session, and has flourished 37.12% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.23% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.76%.
An analysis of the Citius Pharmaceuticals Inc. (NASDAQ:CTXR) stock in terms of its daily trading volume indicates that the 3-month average is 8.24 million. However, this figure increases on the past 10-day timeline to an average of 4.07 million.
Current records show that the company has 137.15M in outstanding shares. The insiders’ percentage holdings are 8.40% of outstanding shares while the percentage share held by institutions stands at 22.20%. The stats also highlight that short interest as of Aug 12, 2021, stood at 13.7 million shares, which puts the short ratio at the time at 4.38. From this we can glean that short interest is 9.38% of company’s current outstanding shares. Notably, we see that shares short in August fall slightly given the previous month’s figure stood at 16.92 million. But the 104.90% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.